Enlivex Therapeutics Ltd.
ENLV
$1.05
-$0.05-4.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -98.92% | 15.96% | 25.22% | 54.48% | -52.52% |
| Total Depreciation and Amortization | -77.64% | 0.63% | -14.89% | -6.00% | -6.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -70.86% | 132.16% | 40.84% | -84.46% | 258.48% |
| Change in Net Operating Assets | 144.82% | -362.63% | 159.25% | -194.41% | 345.54% |
| Cash from Operations | -56.06% | -45.63% | 60.16% | 14.53% | 2.98% |
| Capital Expenditure | -288.89% | 43.75% | 62.79% | -514.29% | 75.86% |
| Sale of Property, Plant, and Equipment | -83.30% | 177,100.00% | -99.55% | 339.22% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 946.17% | 53.02% | -115.84% | 20.19% | 2.94% |
| Cash from Investing | 140.37% | 275.94% | -115.57% | 23.29% | 4.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 662.80% | -94.32% | 715.37% | 252.94% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 200.00% | 89.54% | -- |
| Cash from Financing | 404.40% | -94.34% | 743.32% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 155.15% | -153.06% | 64.39% | 197.37% | 23.56% |